Charanjit Bountra
Direttore/Membro del Consiglio presso CannBioRex Pharmaceuticals Corp.
Posizioni attive di Charanjit Bountra
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
CannBioRex Pharmaceuticals Corp.
 CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | Direttore/Membro del Consiglio | 01/05/2018 | - |
| Independent Dir/Board Member | 01/05/2018 | - | |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - | - |
| University of Oxford (Canada) | Corporate Officer/Principal | - | - |
KYTTARO Ltd.
 KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | Direttore/Membro del Consiglio | 28/07/2021 | - |
Storia della carriera di Charanjit Bountra
Precedenti posizioni note di Charanjit Bountra
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Spinifex Group, Inc.
 Spinifex Group, Inc. Advertising/Marketing ServicesCommercial Services Spinifex Group, Inc. provides advertising agency services. The private company is based in Torrance, CA. | Presidente | - | - |
Statistiche
Distribuzione geografica
| Canada | 4 |
| Stati Uniti | 2 |
| Regno Unito | 2 |
Posizioni
| Director/Board Member | 2 |
| Corporate Officer/Principal | 2 |
| Independent Dir/Board Member | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 4 |
|---|---|
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | Health Technology |
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
Spinifex Group, Inc.
Spinifex Group, Inc. Advertising/Marketing ServicesCommercial Services Spinifex Group, Inc. provides advertising agency services. The private company is based in Torrance, CA. | Commercial Services |
KYTTARO Ltd.
KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | Health Technology |
- Borsa valori
- Insiders
- Charanjit Bountra
- Esperienza
